Reclassification of oligoastrocytomas by loss of heterozygosity studies

被引:34
作者
Eoli, Marica
Bissola, Lorena
Bruzzone, Maria Grazia
Pollo, Bianca
Maccagnano, Carmelo
De Simone, Tiziana
Valletta, Lorella
Silvani, Antonio
Bianchessi, D.
Broggi, Giovanni
Boiardi, Amerigo
Finocchiaro, Gaetano
机构
[1] Ist Nazl Neurol Carlo Besta, Dept Expt Neurosci & Diagnost, I-20133 Milan, Italy
[2] Ist Nazl Neurol Carlo Besta, Dept Clin Neurosci, I-20133 Milan, Italy
[3] Ist Nazl Neurol Carlo Besta, Dept Neurosurg, I-20133 Milan, Italy
关键词
oligoastrocytoma; LOH; 1p; 19q; 17p; 10; MRI;
D O I
10.1002/ijc.21759
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oligoastrocytomas (OAs) are WHO grade 11 or III tumors composed of a mixture of 2 neoplastic cell types morphologically resembling the cells in oligodendrogliomas and diffuse astrocytomas. Investigations on the genetic profile of OAs may yield important information for their classification and help for their clinical management. We have studied, in 94 OAs (46 WHO grade 11 and 48 WHO grade 111), the patterns of loss of heterozygosity (LOH) of 4 genomic regions: 1p, 19q, 17p and 10q. Results were as follows: LOH 1p was present in 46% of the tumors; LOH 19q in 45%; LOH 17p in 22%; LOH 10q in 16%. LOH 1p and 19q were associated in 32%, other LOH associations were rare (< 3%). Patients had a median follow-up of 30 months. Patients without LOH on 1p had shorter progression free survival than patients with LOH on 1p: 30 vs. 132 months, p < 0.0001. MRI indicated that tumors without LOH on 1p were often temporal (p < 0.02), and showed signal inhomogeneity on T1 and T2 images (p < 0.02) and contrast enhancement (p < 0.04). Thus, LOH on 1p identifies two subgroups of OAs. OAs without LOH on 1p behave like WHO grade 11 or III diffuse astrocytomas: they have shorter survival, MRI characteristics implying malignancy and genetic alterations associated with tumor progression. OAs with LOH on 1p, on the other hand, behave like WHO grade If or III oligodendrogliomas with 1p loss: they are associated with longer survival and do not have MRI or genetic alterations associated with malignancy. These findings suggest that the definition of OAs or mixed gliomas could be reshaped in agreement with the genetic information. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:84 / 90
页数:7
相关论文
共 35 条
  • [1] Alonso ME, 2005, ONCOL REP, V13, P539
  • [2] Barbashina V, 2005, CLIN CANCER RES, V11, P1119
  • [3] Barker FG, 1997, CANCER-AM CANCER SOC, V80, P936
  • [4] Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
    Bauman, GS
    Ino, Y
    Ueki, K
    Zlatescu, MC
    Fisher, BJ
    Macdonald, DR
    Stitt, L
    Louis, DN
    Cairncross, JG
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03): : 825 - 830
  • [5] MOLECULAR ANALYSIS OF CHROMOSOME-1 ABNORMALITIES IN HUMAN GLIOMAS REVEALS FREQUENT LOSS OF 1P IN OLIGODENDROGLIAL TUMORS
    BELLO, MJ
    VAQUERO, J
    DECAMPOS, JM
    KUSAK, ME
    SARASA, JL
    SAEZCASTRESANA, J
    PESTANA, A
    REY, JA
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (02) : 172 - 175
  • [6] Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine
    Biemond-ter Stege, EM
    Kros, JM
    de Bruin, HG
    Enting, RH
    van Heuvel, I
    Looijenga, LHJ
    van der Rijt, CDD
    Smitt, PAES
    van den Bent, MJ
    [J]. CANCER, 2005, 103 (04) : 802 - 809
  • [7] Association of chromosome 10 losses and negative prognosis in oligoastrocytomas
    Bissola, L
    Eoli, M
    Pollo, B
    Merciai, BM
    Silvani, A
    Salsano, E
    Maccagnano, C
    Bruzzone, MG
    Conti, AMF
    Solero, CL
    Giombini, S
    Broggi, G
    Boiardi, A
    Finocchiaro, G
    [J]. ANNALS OF NEUROLOGY, 2002, 52 (06) : 842 - 845
  • [8] Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities
    Buckner, JC
    Gesme, D
    O'Fallon, JR
    Hammock, JE
    Stafford, S
    Brown, PD
    Hawkins, R
    Scheithauer, BW
    Erickson, BJ
    Levitt, R
    Shaw, EG
    Jenkins, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 251 - 255
  • [9] Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
    Cairncross, JG
    Ueki, K
    Zlatescu, MC
    Lisle, DK
    Finkelstein, DM
    Hammond, RR
    Silver, JS
    Stark, PC
    Macdonald, DR
    Ino, Y
    Ramsay, DA
    Louis, DN
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) : 1473 - 1479
  • [10] Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results
    Chahlavi, A
    Kanner, A
    Peereboom, D
    Staugaitis, SM
    Elson, P
    Barnett, G
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2003, 61 (03) : 267 - 273